CA2008735C - Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce - Google Patents

Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce Download PDF

Info

Publication number: CA2008735C
Authority: CA; Canada
Prior art keywords: egf; antibodies; receptor; binding; errp
Prior art date: 1990-01-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002008735A

Other languages

English (en)

Other versions

CA2008735A1 (fr

Inventor

Denry J. Sato

Dianging Wu

Lihua Wang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Adirondack Biomedical Research Institute Inc

Original Assignee

Jones W Alton Cell Science Center Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-26

Filing date

1990-01-26

Publication date

2000-03-28

1990-01-26 Application filed by Jones W Alton Cell Science Center Inc filed Critical Jones W Alton Cell Science Center Inc

1990-01-26 Priority to CA002008735A priority Critical patent/CA2008735C/fr

1991-07-26 Publication of CA2008735A1 publication Critical patent/CA2008735A1/fr

2000-03-28 Application granted granted Critical

2000-03-28 Publication of CA2008735C publication Critical patent/CA2008735C/fr

2010-01-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 title claims description 16
102000005962 receptors Human genes 0.000 title abstract description 58
108020003175 receptors Proteins 0.000 title abstract description 58
230000002860 competitive effect Effects 0.000 title description 12
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 title 1
229940116978 human epidermal growth factor Drugs 0.000 title 1
102000001301 EGF receptor Human genes 0.000 claims abstract description 139
108060006698 EGF receptor Proteins 0.000 claims abstract description 56
230000027455 binding Effects 0.000 claims abstract description 55
101710098940 Pro-epidermal growth factor Proteins 0.000 claims abstract 7
210000004027 cell Anatomy 0.000 claims description 48
150000001413 amino acids Chemical group 0.000 claims description 41
210000004408 hybridoma Anatomy 0.000 claims description 27
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 claims description 15
238000000034 method Methods 0.000 claims description 15
150000001875 compounds Chemical class 0.000 claims description 11
230000012010 growth Effects 0.000 claims description 7
210000005260 human cell Anatomy 0.000 claims description 7
238000004925 denaturation Methods 0.000 claims description 6
230000036425 denaturation Effects 0.000 claims description 6
230000002163 immunogen Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 3
230000008569 process Effects 0.000 claims description 2
230000004565 tumor cell growth Effects 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 69
102400001368 Epidermal growth factor Human genes 0.000 description 64
101800003838 Epidermal growth factor Proteins 0.000 description 64
229940116977 epidermal growth factor Drugs 0.000 description 64
229940024606 amino acid Drugs 0.000 description 47
108090000765 processed proteins & peptides Proteins 0.000 description 46
239000012634 fragment Substances 0.000 description 44
235000001014 amino acid Nutrition 0.000 description 43
102000004196 processed proteins & peptides Human genes 0.000 description 19
238000003776 cleavage reaction Methods 0.000 description 18
230000007017 scission Effects 0.000 description 18
125000003275 alpha amino acid group Chemical group 0.000 description 16
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 15
101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 13
239000000872 buffer Substances 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
230000029087 digestion Effects 0.000 description 10
239000000499 gel Substances 0.000 description 10
238000004007 reversed phase HPLC Methods 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
108010051815 Glutamyl endopeptidase Proteins 0.000 description 9
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
239000003446 ligand Substances 0.000 description 9
239000002609 medium Substances 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
235000018417 cysteine Nutrition 0.000 description 8
238000001962 electrophoresis Methods 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
210000004379 membrane Anatomy 0.000 description 8
239000012528 membrane Substances 0.000 description 8
NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 7
108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 7
ZSNFGVQUPMRCIP-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)ON1C(=O)CCC1=O ZSNFGVQUPMRCIP-UHFFFAOYSA-N 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
239000000020 Nitrocellulose Substances 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
229920001220 nitrocellulos Polymers 0.000 description 6
229920001542 oligosaccharide Polymers 0.000 description 6
150000002482 oligosaccharides Chemical class 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
206010041823 squamous cell carcinoma Diseases 0.000 description 6
PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
241000287828 Gallus gallus Species 0.000 description 5
102400001320 Transforming growth factor alpha Human genes 0.000 description 5
101800004564 Transforming growth factor alpha Proteins 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
108010069653 peptide E (adrenal medulla) Proteins 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
108091005804 Peptidases Proteins 0.000 description 4
239000004365 Protease Substances 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
-1 aspartyl-prolyl Chemical group 0.000 description 4
238000003556 assay Methods 0.000 description 4
238000000376 autoradiography Methods 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
238000004132 cross linking Methods 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
238000001262 western blot Methods 0.000 description 4
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
238000009835 boiling Methods 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000009137 competitive binding Effects 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
208000002109 Argyria Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000609499 Palicourea Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
230000010799 Receptor Interactions Effects 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
102000019997 adhesion receptor Human genes 0.000 description 2
108010013985 adhesion receptor Proteins 0.000 description 2
230000004075 alteration Effects 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
108010005636 polypeptide C Proteins 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000013598 vector Substances 0.000 description 2
ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
SNPQGCDJHZAVOB-SOMABOLJSA-N D-glucosyl-N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-SOMABOLJSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241001622557 Hesperia Species 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102000008192 Lactoglobulins Human genes 0.000 description 1
108010060630 Lactoglobulins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
101500027531 Rattus norvegicus Transforming growth factor alpha Proteins 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
238000000819 phase cycle Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA002008735A 1990-01-26 1990-01-26 Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce Expired - Lifetime CA2008735C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002008735A CA2008735C (fr)	1990-01-26	1990-01-26	Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002008735A CA2008735C (fr)	1990-01-26	1990-01-26	Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce

Publications (2)

Publication Number	Publication Date
CA2008735A1 CA2008735A1 (fr)	1991-07-26
CA2008735C true CA2008735C (fr)	2000-03-28

Family

ID=4144141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002008735A Expired - Lifetime CA2008735C (fr)	1990-01-26	1990-01-26	Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce

Country Status (1)

Country	Link
CA (1)	CA2008735C (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN102262155A (zh) *	2011-04-12	2011-11-30	百泰生物药业有限公司	重组人表皮生长因子生物学活性测定方法及其应用

1990
- 1990-01-26 CA CA002008735A patent/CA2008735C/fr not_active Expired - Lifetime

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN102262155A (zh) *	2011-04-12	2011-11-30	百泰生物药业有限公司	重组人表皮生长因子生物学活性测定方法及其应用
CN102262155B (zh) *	2011-04-12	2013-10-09	百泰生物药业有限公司	重组人表皮生长因子生物学活性测定方法及其应用

Also Published As

Publication number	Publication date
CA2008735A1 (fr)	1991-07-26

Legal Events

Date	Code	Title	Description
1997-01-15	EEER	Examination request
2010-01-26	MKEX	Expiry
2023-05-26	MKEX	Expiry	Effective date: 20100126

Publication	Publication Date	Title
US5459061A (en)	1995-10-17	Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
Wu et al.	1989	Human epidermal growth factor (EGF) receptor sequence recognized by EGF competitive monoclonal antibodies: Evidence for the localization of the EGF-binding site
Holmes et al.	1992	Identification of heregulin, a specific activator of p185erbB2
EP0683234B1 (fr)	2003-05-07	Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation
EP0584125B1 (fr)	1997-07-16	Formes tronquees du recepteur de facteur de croissance des hepatocytes
Chernousov et al.	1991	Role of the I-9 and III-1 modules of fibronectin in formation of an extracellular fibronectin matrix
Klagsbrun et al.	1986	Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor.
US5955317A (en)	1999-09-21	Antibodies to β-amyloids or their derivatives and use thereof
CA1340977C (fr)	2000-04-25	Recepteur proteique capteur, ainsi que son anticorps
JP3039802B2 (ja)	2000-05-08	繊維芽細胞成長因子のための受容体
EP1350799A2 (fr)	2003-10-08	Polypeptides d'immunoglobulines inhibiteurs se liant au récepteur-beta humain de PDGF
CA2008735C (fr)	2000-03-28	Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce
AU9499898A (en)	1999-04-12	Mutants of thyroid stimulating hormone and methods based thereon
CA2147875C (fr)	2002-04-02	Crf-proteine liante
EP0640100A1 (fr)	1995-03-01	Modulation des interactions entre cd36 et la thrombospondine
TAM et al.	1991	Mapping the receptor‐recognition site of human transforming growth factor‐α
WO1994012531A1 (fr)	1994-06-09	Antagonistes de l'interferon gamma humain
JP3232415B2 (ja)	2001-11-26	モノクローナル抗体，その製造法および用途
AU2005252297A1 (en)	2005-12-22	Heparin binding peptide
JPH03502446A (ja)	1991-06-06	動物およびヒトのレクチン類の少なくとも一部分の配列を再現するアミノ酸配列，それを得る方法，およびその診断および治療への用途
Théveniau et al.	1989	Antipeptide antibodies to the 141-1141-1141-1receptor confirm the extracellular orientation of the amino-terminus and the putative first extracellular loop
AU672377C (en)	1998-08-20	Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
Molday et al.	1992	Molecular properties of the cGMP-gated cation channel of rod photoreceptor cells as probed with monoclonal antibodies
JP3024987B2 (ja)	2000-03-27	抗体、その製造法および用途
Gregor	1990	Molecular structure of the kainate-binding protein, a member of the glutamate receptor gene family, from chick cerebellum